Clinical Trials

98 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT06827054 2026-02-18

Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids

20 enrolled

Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT06943664 2026-02-18

Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06224673 2026-02-13

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

36 enrolled

Triple Negative Breast Neoplasms

NCT07405086 2026-02-12

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

160 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07393555 2026-02-06

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

117 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

43 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07349771 2026-01-20

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

72 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT07323641 2026-01-07

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06858501 2025-12-31

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

84 enrolled

CNS

Ganglioneuroblastoma

NCT07293403 2025-12-19

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

25 enrolled

Lymphoid

Lymphoma, T-Cell

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT07276360 2025-12-11

HypoRTCx-UG

278 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07191717 2025-11-10

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

42 enrolled

Anatomic Stage I Breast Cancer AJCC v8

NCT07226544 2025-11-10

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

31 enrolled

Carcinoma, Renal Cell

NCT07218692 2025-10-20

RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

35 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07037004 2025-09-23

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

62 enrolled

Carcinoma, Renal Cell

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

90 enrolled